At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 43 enrolled
Drug / intervention
Ixazomib +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1 Pharmacokinetic and Tolerability Study of Oral MLN9708 Plus Lenalidomide and Dexamethasone in Adult Asian Patients With Relapsed and/or Refractory Multiple Myeloma
In Brief
A Phase 1 clinical trial evaluating Ixazomib, Lenalidomide, and 1 other intervention for Multiple Myeloma. Completed, enrolled 43 participants across 5 sites in 3 countries.
Detailed Summary
The purpose of this Phase 1 study is to characterize the pharmacokinetic (PK) and tolerability of oral ixazomib (MLN9708) when administered in combination with lenalidomide and dexamethasone in adult Asian participants with relapsed and/or refractory multiple myeloma.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMultiple Myeloma
CountriesHong Kong, Singapore, South Korea
Collaborators--
Timeline
Phase 1CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedJul 2012
Enrollment StartDec 2012
Primary CompletionJul 2014
Study CompletionApr 2017
TodayJul 2026
First PostedJul 20, 2012
Enrollment StartDec 17, 2012
Primary CompletionJul 14, 2014
Study CompletionApr 11, 2017
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 14.0 years ago
Interventions
Ixazomibdrug
Ixazomib capsules
Lenalidomidedrug
Lenalidomide capsules
Dexamethasonedrug
Dexamethasone tablets